LONDON, UK — Ticagrelor ( Brilinta, Brilique , AstraZeneca) did not demonstrate a clinical benefit over clopidogrel in the Examining Use of Ticagrelor in Peripheral Artery Disease (PAD) (EUCLID) trial, according to top-line results announced by ... Dermatology Online Journal, 2 weeks ago
Ticagrelor (Brilinta) Fails to Improve Peripheral Artery Disease in Late-Stage Study - PT Community, 2 weeks ago
GW27-e0424 Comparison of Ticagrelor with Clopidogrel in Patients with Acute Coronary Syndromes Undergoing DES ImplantationJournal of the American College of Cardiology, 1 week ago GW27-e0576 Relevance of the CYP2C19 Polymorphism for Loading and Maintenance dose of Prasugrel and Clopidogrel Treatment Effect in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: The PRAISE-GENE Study Journal of the American College of Cardiology, 1 week ago GW27-e0058 Comparisons of loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction Journal of the American College of Cardiology, 1 week ago Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatm Laryngoscope Investigative Otolaryngology, 2 weeks ago
* Brilinta fails to show benefit over clopidogrel in PAD * Follows failure of heart drug in stroke trial in March * Executive says $3.5 bln drug sales target not attainable * Drugmaker sells rights to Toprol-XL for up to $223 mln (Adds executive ...CNBC, 2 weeks ago UPDATE 1-AstraZeneca's Brilinta drug fails in big arterial disease trial Business Insider, 2 weeks ago AstraZeneca cuts Brilinta sales hopes on artery disease failure Yahoo! Finance UK and Ireland, 2 weeks ago AstraZeneca's Brilinta drug fails in big arterial disease trial Yahoo! Finance, 2 weeks ago
Investigators at RIKEN Report Findings in Clopidogrel Therapy (Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a...
Investigators at RIKEN Report Findings in Clopidogrel Therapy (Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information) By a News ...4 Traders, 2 days ago Human medicines European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate), clopidogrel, Revision: 9, Authorised European Medicines Agency, 3 weeks ago
Prof-Research The ' Global and Chinese Clopidogrel Impurity Industry, 2011-2021 Market Research Report ' is a professional and in-depth study on the current state of the global Clopidogrel Impurity industry with a focus on the Chinese market. The ...MarketResearch.com, 3 days ago 2016 Global and Chinese Clopidogrel Bisulfate Industry Market Research Report MarketResearch.com, 1 month ago Global Ticagrelor Market Growth and Forecast to 2027 Before It's News, 1 month ago
GW27-e0655 Head to head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in the Chinese acute myocardial infarction patients underwent percutaneous coronary interventionJournal of the American College of Cardiology, 1 week ago
GW27-e0776 Impacts of Different Serum Glucose Level on The Anti-Platelet Effect of Clopidogrel and Ticagrelor in Patients with Acute Myocardial Infarction Complicated by Type 2 DiabetesJournal of the American College of Cardiology, 1 week ago
GW27-e0434 Impact of CYP2C19 variants on drug efficacy of clopidogrel and 1-year clinical outcomes in coronary heart patients undergoing PCIJournal of the American College of Cardiology, 1 week ago
Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel
Introduction Currently, the low-response or non-response to clopidogrel treatment in cardiovascular diseases is of increasing concern, particularly in the condition of acute coronary syndrome (ACS) or clopidogrel resistance (CR) ( Nguyen et al., ...Frontiers in Neurorobotics, 2 weeks ago
Top-line results of the EUCLID trial did not demonstrate a benefit of ticagrelor over clopidogrel for prevention of atherothrombotic events in patients with symptomatic peripheral artery disease, according to a press release issued by ...Healio, 2 weeks ago Study: AstraZeneca's Brilinta fails to best clopidogrel in patients with peripheral artery disease FirstWord Pharma, 2 weeks ago AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease PressReleasePoint, 2 weeks ago AstraZeneca : 4 October 2016 AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease Corporate Press Release 4 Traders, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!